Filing Flows › Biocryst Pharmaceuticals (BCRX) › Q3 2026
Biocryst Pharmaceuticals (BCRX) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Biocryst Pharmaceuticals (BCRX) reported revenue of $180M for the third quarter 2026 (Q3 2026), +13% from a year earlier and -17% from the quarter before. Operating margin was 29.6%, net earnings $37.9M (21.0% of revenue).
Biocryst Pharmaceuticals, Q3 2026: revenue $180M (+13% year over year), operating margin 29.6%, net earnings $37.9M, operating cash flow $33.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $180M | -17% | +13% |
| Operating profit | $53.3M | -46% | +80% |
| Net earnings | $37.9M | -52% | +194% |
| Operating cash flow | $33.0M | -68% | -21% |
| Free cash flow | $32.8M | -69% | -19% |
What changed
Revenue was $180.3M in Q3 2026, up 13% year over year and down 17% from the previous quarter. Product was the largest line at 96% of revenue. Product added $14.6M year over year (up 9%), 70% of the total change.
Operating profit was $53.3M, a 29.6% margin (up 11.0 points year over year). Of the extra revenue versus Q3 2025, 114% reached operating profit, above the 19% margin then. Total costs fell 2% while revenue rose 13%. The fastest-growing cost line was Research & development (+31%). Net earnings were $37.9M, up 194% year over year. The effective tax rate was 1.7%.
Operating cash flow was $33.0M (down 21% year over year), 87% of net earnings. Non-cash charges added back $244K of depreciation and amortization and $14.2M of share-based compensation. Working capital and other items used $19.4M. Capital expenditures of $233K left free cash flow of $32.8M.
Questions
What was Biocryst Pharmaceuticals' revenue in the third quarter 2026?
Biocryst Pharmaceuticals (BCRX) reported revenue of $180M for the third quarter 2026 (Q3 2026), +13% from a year earlier and -17% from the quarter before.
Was Biocryst Pharmaceuticals profitable in the third quarter 2026?
Operating profit was $53.3M (29.6% of revenue) and net earnings $37.9M.